Results 191 to 200 of about 136,011 (340)

Enhancement of radiation response with bevacizumab

Journal of Experimental & Clinical Cancer Research, 2012
Background Vascular endothelial growth factor (VEGF) plays a critical role in tumor angiogenesis. Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF.
Hoang Tien, Huang Shyhmin, Armstrong Eric, Eickhoff Jens C, Harari Paul M   +4 more
doaj   +1 more source

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab [PDF]

arXiv
Background: Evidence maps have been used in healthcare to understand existing evidence and to support decision-making. In oncology they have been used to summarise evidence within a disease area but have not been used to compare evidence across different diseases.
arxiv  

Bevacizumab for Retinopathy of Prematurity [PDF]

New England Journal of Medicine, 2011
Anna L. Ells, Jayne E Camuglia, Glen A. Gole   +2 more
openaire   +8 more sources

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Advanced‐stage EGFR‐mutated lung non‐small cell lung cancer (NSCLC) challenges current treatment paradigms, particularly after frontline EGFR‐TKI therapy failure. This study investigates the survival impact of combined anti‐angiogenic agent and immunochemotherapy (AICT) for this population.
Yi‐Tse Su, Shu‐Farn Tey, Chung‐Ta Lee, Chien‐Yu Lin, Jeng‐Shiuan Tsai, Chien‐Chung Lin, Chin‐Wei Kuo   +6 more
wiley   +1 more source

Bevacizumab (Avastin) and Thermal Laser Combination Therapy for Peripapillary Choroidal Neovascular Membranes

Journal of Ophthalmology, 2017
Objective. This is a retrospective interventional case series describing the results of 5 eyes from 5 patients with symptomatic peripapillary choroidal neovascularization (CNVM) receiving initial bevacizumab treatment followed by thermal laser and ...
Sean D. Adrean, Scott Grant, Siyang Chaili   +2 more
doaj   +1 more source

Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data [PDF]

, 2004
Hope S. Rugo
openalex   +1 more source

Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab [PDF]

, 2004
Nishan H. Fernando, Herbert I. Hurwitz
openalex   +1 more source

Expanding the Clinical Development of Bevacizumab [PDF]

, 2004
Helen X. Chen
openalex   +1 more source

Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer [PDF]

arXiv
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-
arxiv  

Reply to “PET concerns in bevacizumab treatment” [PDF]

, 2004
Christopher G. Willett, D. G. Duda, Alan J. Fischman, Rakesh K. Jain   +3 more
openalex   +1 more source